Gut Liver.
2017 Mar;11(2):270-275. 10.5009/gnl16163.
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
- Affiliations
-
- 1Health Care Center, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
- 2Department of Internal Medicine, Kangwon National University College of Medicine, Chuncheon, Korea.
- 3Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
- 4Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- 5Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
- 6Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
- 7Department of Internal Medicine, Gimpo Woori Hospital, Gimpo, Korea.
- 8Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- 9Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
- 10Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea. sanghoon@hallym.or.kr
- KMID: 2412194
- DOI: http://doi.org/10.5009/gnl16163
Abstract
- BACKGROUND/AIMS
Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and available treatment outcomes of patients with genotype 6 HCV in Korea.
METHODS
From 2004 to 2014, data were collected from Korean patients infected with genotype 6 HCV in eight hospitals.
RESULTS
Thirty-two patients had genotype 6 HCV. The median age was 44 years, and 6c was the most common subtype. The baseline median alanine transaminase level was 88 (21 to 1,019) IU/mL, and the HCV RNA level was 1,405,000 (96,500 to 28,844,529) IU/mL. Twenty-five patients were treated with peginterferon (PEG-IFN) and ribavirin. Three follow-up losses occurred. Additionally, 13 patients attained a sustained virologic response (SVR), seven patients relapsed, and two patients exhibited a null response. The SVR rates were 40% and 75% for the 24- and more than 48-week treatments, respectively, and five of the six patients who achieved a rapid virologic response (RVR) attained a SVR.
CONCLUSIONS
Korean patients infected with genotype 6 HCV are relatively young, and 6c is the most common subtype. When treated with PEG-IFN and ribavirin, the SVR rate was 52%. Similar to other genotypes, a longer duration of treatment and attainment of RVR are important for SVR.
MeSH Terms
-
Adult
Antiviral Agents/*administration & dosage
Drug Therapy, Combination
Female
Genotype
Hepacivirus/*genetics
Hepatitis C/*drug therapy/virology
Humans
Interferon-alpha/*administration & dosage
Male
Middle Aged
Polyethylene Glycols/*administration & dosage
Republic of Korea
Retrospective Studies
Ribavirin/*administration & dosage
Sustained Virologic Response
Antiviral Agents
Interferon-alpha
Polyethylene Glycols
Ribavirin
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
- Treatment of chronic hepatitis C: Efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients
- Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection
- Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
- Permanent sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment
